関連する実験動画
Updated: Nov 12, 2025

08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.5K
慢性腎疾患における心血管疾患: 病理生理学的洞察と治療の選択肢
Joachim Jankowski1,2, Jürgen Floege3, Danilo Fliser4
1Institute for Molecular Cardiovascular Research (J.J.), University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Aachen, Germany.
Circulation
|March 15, 2021
まとめ
慢性腎疾患 (CKD) の患者は,特に進行した段階で,心血管疾患のリスクが著しく高まります. 主な死因は腎不全ではなく 心血管疾患で 標的を絞った介入の緊急性が強調されています
科学分野:
- 腎臓科
- 心臓病科
- 内科 医学
背景:
- 慢性腎臓病 (CKD) の患者は,心不全や突然の心臓死などの心血管疾患のリスクが大幅に増加します.
- このリスクは,特に進行したCKD (CKD ステージ4〜5) で,CKDの進行とともに著しく増加します.
研究 の 目的:
- 慢性腎臓病患者の心血管疾患 (CVD) の現在の理解を要約する.
- この高リスク集団におけるCVDの臨床的影響を概説する.
主な方法:
- この記事は,既存の研究と臨床知識を統合した概要です.
- 慢性腎臓病と 心血管病理を結びつけるメカニズムに焦点を当てています
主要な成果:
- 慢性腎臓病は慢性炎症を誘発し 心血管の老化を加速します
- 病理的変化には,動脈硬化,血管および心筋の化,血管老化,心筋線維症が含まれます.
結論:
- 心血管疾患は,進行したCKDにおける死亡率の主な原因で,末期腎臓疾患を上回っています.
- CKDは心臓血管の老化を加速し,CKDの管理において心臓血管の健康に重点を置く必要があります.
関連する概念動画
Chronic Kidney Disease III: Interprofessional Care
189
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
189
Chronic Kidney Disease I: Introduction
344
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
344
Chronic Kidney Disease IV: Nursing Management
132
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
132
Chronic Kidney Disease II: Clinical Manifestations
284
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
284
Heart Failure Drugs: Diuretics
596
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
596
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
657
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
657

